Oncology

The FDA approved the first-in-class targeted therapy based on a clinical trial evaluating overall survival among adults with previously treated metastatic pancreatic adenocarcinoma.

Intismeran autogene plus pembrolizumab met the primary recurrence-free survival and a key secondary distant metastasis-free survival endpoint in the phase 3 INTerpath-001 trial in patients with completely...

The FDA granted accelerated approval to Zenbexus (iberdomide) in combination with daratumumab, hyaluronidase-fihj, and dexamethasone for adults with multiple myeloma previously treated with a proteasome...

In this video, Brittany Watson, MD, MPH, FAAFP, DABOM and Joseph Mikhael, MD, MEd, FRCPC, FACP, discuss the role of primary care in the early recognition and diagnosis of multiple myeloma, including the...

An integrated UK Biobank and preclinical study linked obesity-related metabolic inflammation to PTPN11-mutant myeloid leukemia and found that combined GLP-1R agonism and IL-17A blockade reduced leukemic...

A pan-cancer modeling study found that COMPASS predicted immune checkpoint inhibitor response across 16 clinical cohorts and achieved higher average accuracy and area under the precision-recall curve than...

In a multicenter dose de-escalation and expansion study of adults with HIV-related DLBCL, ibrutinib plus R-da-EPOCH showed manageable toxicity and clinical activity, with 3-year event-free and overall...

FDA expanded perioperative pembrolizumab-based treatment options for adults with muscle-invasive bladder cancer.

July 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...

The FDA approved subcutaneous isatuximab-irfc (Sarclisa Escena, Sanofi-Aventis US LLC) for multiple myeloma treatment regimens across relapsed, refractory, and newly diagnosed disease settings.